Suven Life Sciences 대차 대조표 상태

재무 상태 기준 확인 5/6

Suven Life Sciences 의 총 주주 지분은 ₹1.9B 이고 총 부채는 ₹0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 ₹2.1B 및 ₹192.8M 입니다.

주요 정보

부채 비율

₹0

부채

이자 보상 비율	n/a
현금	₹1.66b
주식	₹1.93b
총 부채	₹192.80m
총 자산	₹2.12b

최근 재무 상태 업데이트

Suven Life Sciences (NSE:SUVEN) Is In A Good Position To Deliver On Growth Plans

Oct 26

Companies Like Suven Life Sciences (NSE:SUVEN) Are In A Position To Invest In Growth

Jun 21

Recent updates

Suven Life Sciences (NSE:SUVEN) Is In A Good Position To Deliver On Growth Plans

Oct 26

Companies Like Suven Life Sciences (NSE:SUVEN) Are In A Position To Invest In Growth

Jun 21

How Much Did Suven Life Sciences'(NSE:SUVEN) Shareholders Earn From Share Price Movements Over The Last Year?

Aug 26

재무 상태 분석

단기부채: SUVEN 의 단기 자산 ( ₹1.9B )이 단기 부채( ₹179.3M ).

장기 부채: SUVEN 의 단기 자산( ₹1.9B )이 장기 부채( ₹13.5M ).

부채 대 자본 내역 및 분석

부채 수준: SUVEN 부채가 없습니다.

부채 감소: SUVEN 는) 부채 대 자기자본 비율이 13.2% 였던 5년 전과 비교하여 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: SUVEN 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 8.5 %의 역사적 비율로 계속 감소할 경우 SUVEN 의 현금 활주로는 1년 미만입니다.

Suven Life Sciences 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Suven Life Sciences (NSE:SUVEN) Is In A Good Position To Deliver On Growth Plans

Companies Like Suven Life Sciences (NSE:SUVEN) Are In A Position To Invest In Growth

Recent updates

Second quarter 2025 earnings released: ₹2.27 loss per share (vs ₹0.58 loss in 2Q 2024)

Suven Life Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Suven Pharma Announces Board Changes

Suven Life Sciences Limited Announces Step Down of Vaidheesh Annaswamy as Executive Chairperson and Director

Suven Life Sciences Announces Positive Topline Results from Phase-2A Proof-Of-Concept Signal Detection Open Label Study of Ropanicant (Suvn-911) for the Treatment of Moderate to Severe Major Depressive Disorder

Suven Life Sciences Announces FDA Acceptance of Investigational New Drug (IND) and Grant of Study May Proceed Letter to Initiate Phase-1 Clinical Trial of SUVN-I6107

New minor risk - Share price stability

First quarter 2025 earnings released: ₹1.29 loss per share (vs ₹1.10 loss in 1Q 2024)

Suven Life Sciences Limited to Report Q1, 2025 Results on Aug 05, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.92 loss per share (vs ₹2.90 loss in 3Q 2023)

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Life Sciences Limited to Report Q3, 2024 Results on Jan 30, 2024

New major risk - Share price stability

Suven Life Sciences Limited to Report Q4, 2024 Results on May 15, 2024

Second quarter 2024 earnings released: ₹0.58 loss per share (vs ₹1.59 loss in 2Q 2023)

New minor risk - Share price stability

Suven Life Sciences Limited to Report Q2, 2024 Results on Nov 04, 2023

Suven Life Sciences (NSE:SUVEN) Is In A Good Position To Deliver On Growth Plans

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.05 loss in FY 2022)

Companies Like Suven Life Sciences (NSE:SUVEN) Are In A Position To Invest In Growth

Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.57 loss in FY 2022)

Third quarter 2023 earnings released: ₹2.90 loss per share (vs ₹2.65 loss in 3Q 2022)

Suven Life Sciences Limited to Report Q3, 2023 Results on Feb 02, 2023

Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

Price target decreased to ₹306

Insufficient new directors

Second quarter 2023 earnings released

Suven Life Sciences Limited to Report Q2, 2023 Results on Nov 08, 2022

Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022

Suven Life Sciences Limited to Report Q1, 2023 Results on Jul 26, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited Declares One-Time Special Dividend for the Financial Year 2021-22, Payable on and from 25 May, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited, Annual General Meeting, Aug 04, 2022

Suven Life Sciences Limited to Report Q4, 2022 Results on May 07, 2022

Price target decreased to ₹306

Insufficient new directors

Suven Life Sciences Limited Declares Interim Dividend, Payable on and from 22 February 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: ₹2.22 loss per share (vs ₹1.23 loss in 2Q 2021)

Price target decreased to ₹306

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Price target increased to ₹472

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Suven Life Sciences Limited announced that it has received INR 369.10425 million in funding from Jasti Family Trust

Independent Non-Executive Director has left the company

Third quarter 2021 earnings released: ₹1.92 loss per share (vs ₹1.79 loss in 3Q 2020)

Suven Life Sciences Limited to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: ₹57.90

First half earnings released

New 90-day high: ₹56.45

Insider recently bought ₹1.0m worth of stock

How Much Did Suven Life Sciences'(NSE:SUVEN) Shareholders Earn From Share Price Movements Over The Last Year?

New 90-day high - ₹54.50

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 17, 2020

First quarter earnings released

New 90-day high - ₹48.50

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 11, 2020

Price target raised to ₹537

Suven Life Sciences Limited(BSE:530239) dropped from S&P Global BMI Index

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표